RESUMEN
Lupus erythematosus panniculitis is a quite rare clinical entity characterised by one or several firm, asymptomatic, often fairly large subcutaneous nodules, as a manifestation of SLE or DLE. Two cases of lupus panniculitis, both female, are described here. Both of them had absence of typical lesions of SLE or DLE elsewhere in the body. Systemic symptoms were not present, antinuclear factor was positive in one case. Both showed typical lobular panniculitis on biospy and responded favourably to systemic chloroquine therapy.
RESUMEN
A case of steatocystoma multiplex in a 45-year-old male is reported. The diagnosis was based on clinical as well as histopathological findings.
RESUMEN
A 45-year old female presented with recurrent eruption of polycyclic erythematous lesion for nearly 2 years. During this period of observation no cause could be determined. Biopsy report was consistent with diagnosis of erythema annulare centrifugum.
RESUMEN
This is a report of tuberous sclerosis in members of three generations originating from parents, both suffering from the disease. Out of 12 family members only two were exempted and clinical expression varied from minimum lesion like adenoma sebaceum only to severe mental retardation and epilepsy.
Asunto(s)
Inmunoensayo/métodos , Medicina Tropical/métodos , Amebiasis/diagnóstico , Amebiasis/inmunología , Hepatitis/diagnóstico , Hepatitis/inmunología , Humanos , Lepra/diagnóstico , Lepra/inmunología , Juego de Reactivos para Diagnóstico , Tuberculosis/diagnóstico , Tuberculosis/inmunología , Fiebre Tifoidea/diagnóstico , Fiebre Tifoidea/inmunologíaAsunto(s)
Lepra/tratamiento farmacológico , Metronidazol/uso terapéutico , Adulto , Humanos , MasculinoRESUMEN
Corticosteroids are known to influence the hypersensitivity reaction in a number of diseases involving hypersensitivity of tissues and alter the antigen antibody reactions in vivo. Corticosteroids administered in thirty tuberculoid cases for a period of 3 weeks showed negative response in the lepromin positive cases uniformly thereby proving suppression of cell mediated immunity in tuberculoid cases under the influence of corticosteroids; hence polar concept of tuberculoid type may be under question with continuous and prolonged corticosteroid therapy under necessity.
Asunto(s)
Betametasona/farmacología , Lepromina/inmunología , Lepra/inmunología , Adolescente , Adulto , Niño , Humanos , Hipersensibilidad Tardía , Masculino , Persona de Mediana EdadRESUMEN
In an international multicentre controlled single-blind trial of 93 previously untreated lepromatous leprosy patients the therapeutic effects of adding rifampicin, 450 mg/day orally or 1,200 mg once monthly in a single oral dose, to dapsone (50 mg/day orally) for the first 6 months of treatment were compared. Clinical and histopathological improvements and bacteriological regression, indicated by the decreases in the bacterial and morphological indices of the skin and nose-blow smears, were satisfactory and practically identical after 6 months' treatment. The once-monthly rifampicin schedule was better tolerated than the daily one. In view of the good therapeutic efficacy and tolerability, the much lower cost of treatment (about one-tenth of that of the daily rifampicin regimen) and the possibility of administration under supervision, once-monthly rifampicin given in a single oral 1,200 mg dose should be recommended, along with a standard dapsone regimen, for large-scale, initial, and intensive combination treatment of patients with lepromatous and borderline-lepromatous leprosy, to help prevent an increase in dapsone resistance. A third antileprosy drug (e.g., clofazimine) may be added to this initial dual-treatment regimen.
Asunto(s)
Dapsona/administración & dosificación , Lepra/tratamiento farmacológico , Rifampin/administración & dosificación , Adolescente , Adulto , Anciano , Niño , Ensayos Clínicos como Asunto , Quimioterapia Combinada , Femenino , Humanos , Masculino , Métodos , Persona de Mediana Edad , Distribución AleatoriaRESUMEN
A comparative study with 2 tier and 3 tier combination of Rifampicin, Clofazimine, DDS, INAH and Thiacetazone was conducted on fifty lepromatous leprosy cases for varying periods. Assessment showed that 2 tier combination of clofazimine and DDS produced good results but the cost stood in the way; whereas 3 tier combination of DDS, thiacetazone and INAH also yielded good results with much less expenses to be incurred by the patients. Whether therapy with this 3 tier combination could be continued for a longer period with sustained improvement is yet to be assessed by further studies for a considerable period.
Asunto(s)
Lepra/tratamiento farmacológico , Adolescente , Adulto , Niño , Clofazimina/uso terapéutico , Dapsona/uso terapéutico , Quimioterapia Combinada , Femenino , Humanos , Isoniazida/uso terapéutico , Masculino , Persona de Mediana Edad , Rifampin/uso terapéutico , Tioacetazona/uso terapéuticoRESUMEN
A comparative study with 2 tier and 3 tier combination of Rifampicin, Clofazimine, DDS, INAH and Thiacetazone was conducted on fifty lepromatous leprosy cases for varying periods. Assessment showed that 2 tier combination of clofazimine and DDS produced good results but the cost stood in the way; whereas 3 tier combination of DDS, thiacetazone and INAH also yielded good results with much less expenses to be incurred by the patients. Whether therapy with this 3 tier combination could be continued for a longer period with sustained improvement is yet to be assessed by further studies for a considerable period.